 |
Vol.52 No.3 contents | Japanese/English |
 | Full Text of PDF (541K) Article in Japanese |
- Case Report -
A Case of EGFR-wild-type Adenocarcinoma of Recurrent Non-small Cell Lung Cancer Responding to Erlotinib
Masami Morimoto1, Naoki Hino1, Hisashi Matsuoka1, Takanori Miyoshi1, Masaru Tsuyuguchi11Department of Surgery, Tokushima Municipal Hospital, Japan
Background. The efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) depends on EGFR-mutation status in patients with non-small cell lung cancer (NSCLC). According to some reports, NSCLC patients with EGFR-wild-type tumor have a favorable clinical response to EGFR-TKI erlotinib. However, erlotinib has not been reported to control EGFR-wild-type tumors completely for the long periods, following discontinuation. Case. A 81-year-old man with an EGFR-wild-type adenocarcinoma of lung (pathological stage I) was treated by some undetermined kind of chemotherapy for recurrent foci of the lung. They responded to erlotinib well and disappeared completely on a computerized tomography imaging. The adverse reactions resulted in the discontinuation of erlotinib, but the survival time from discontinuation was 30 months. Conclusion. Erlotinib is a treatment option for EGFR-wild-type NSCLC.
key words: Lung cancer, EGFR-TKI, Erlotinib, EGFR-mutation
Received: December 26, 2011
Accepted: May 25, 2012
JJLC 52 (3): 315-319, 2012
